Skip to main content
Signal8
Launch Terminal

LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc.

NASDAQ:LENZHealthcare
-12.61%$3.05
AH$3.09+1.31%vs close
Mkt Cap$95.83M
Float–
O/S31.42M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
LENZ Therapeutics, Inc. logoNASDAQ:LENZ$3.05-12.61%
Phase Distribution
8 lead-sponsored trials·0 active·8 completed
Phase 11
Phase 24
Phase 33
(2 more as collaborator)
Status Overview
Completed8

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Phase
  • Phase 3
    Completed

    Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

    Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution

    Presbyopia, Refractive Error +2

    Enrollment
    469
    Start
    Dec 2022
    Primary Completion
    Dec 2023
    Completion
    Jan 2024
    NCT05656027
  • Phase 3
    Completed

    Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

    Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution

    Presbyopia, Near Vision +2

    Enrollment
    229
    Start
    Mar 2023
    Primary Completion
    Dec 2023
    Completion
    Jan 2024
    NCT05728944
  • Phase 3
    Completed

    Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

    Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution

    Presbyopia, Near Vision +2

    Enrollment
    362
    Start
    Feb 2023
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05753189
  • Phase 2
    Completed

    Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

    PRX-100, Placebo

    Presbyopia

    Enrollment
    20
    Start
    Sep 2015
    Primary Completion
    Nov 2015
    Completion
    Nov 2015
    NCT02554396
  • Phase 2
    Completed

    A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

    Aceclidine+tropicamide combination, Aceclidine

    Presbyopia

    Enrollment
    58
    Start
    Apr 2017
    Primary Completion
    May 2018
    Completion
    May 2018
    NCT03201562
  • Phase 2
    Completed

    Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

    Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution

    Presbyopia, Refractive Errors +1

    Enrollment
    68
    Start
    May 2022
    Primary Completion
    Aug 2022
    Completion
    Sep 2022
    NCT05294328
  • Phase 2
    Completed

    Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

    Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution

    Presbyopia, Refractive Errors +1

    Enrollment
    59
    Start
    Aug 2022
    Primary Completion
    Dec 2022
    Completion
    Dec 2022
    NCT05431543
  • Phase 1
    Completed

    Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

    Aceclidine + Brimonidine, Aceclidine

    Eye Diseases, Presbyopia +4

    Enrollment
    30
    Start
    Jul 2023
    Primary Completion
    Oct 2023
    Completion
    Oct 2023
    NCT05936489
Search ClinicalTrials.gov for “LENZ Therapeutics”